NeoGenomics (NEO) Stock Price, News & Analysis

Company Overview

NeoGenomics, Inc. (NASDAQ: NEO) is a leading provider of cancer-focused genetic and molecular diagnostic testing services. Founded in 2002 and headquartered in Fort Myers, Florida, the company has built a reputation for delivering high-complexity laboratory testing that supports personalized oncology care. NeoGenomics offers an extensive menu of assays designed to aid in diagnosis, prognosis and therapy selection for a broad range of hematologic and solid tumor cancers.

The company’s core services include next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), cytogenetics, immunohistochemistry (IHC) and flow cytometry, complemented by digital and computational pathology. In addition to clinical testing, NeoGenomics operates a central laboratory services division that provides biomarker testing and companion diagnostics for pharmaceutical and biotechnology companies conducting oncology clinical trials. The integration of laboratory information systems and advanced analytics enables streamlined sample processing and rapid reporting of results.

NeoGenomics has grown through both organic expansion and strategic acquisitions, including the purchase of a leading immunohistochemistry laboratory in 2014 and several specialty genetic testing firms in subsequent years. Its network spans multiple U.S. laboratories in Florida, California, Texas, Tennessee, Washington, New York and New Jersey, alongside European facilities in Basel, Switzerland; Glasgow, U.K.; and Hamburg, Germany. This global footprint allows the company to serve healthcare providers, research institutions and clinical trial sponsors around the world.

Under the leadership of President and Chief Executive Officer Mark J. Erceg and a seasoned management team, NeoGenomics remains focused on advancing cancer diagnostics through technology innovation and rigorous quality standards. The company continues to invest in expanding its test menu, enhancing automation and incorporating new molecular techniques to support precision medicine initiatives and improve outcomes for patients with cancer.

Key Stats

• Today's Range: $7.40 to $7.70
• 50-Day Range: $6.39 to $9.97
• 52-Week Range: $6.08 to $19.12
• Volume: 1.11 million shs
• Average Volume: 1.29 million shs
• Market Capitalization: $980.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.83
• Consensus Rating: Hold

NeoGenomics Stock Analysis - MarketRank™

NeoGenomics scored higher than 73% of companies evaluated by MarketBeat, and ranked 238th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

NeoGenomics has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 5 buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

NeoGenomics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NeoGenomics are expected to grow in the coming year, from ($0.20) to $0.09 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NeoGenomics is -12.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeoGenomics is -12.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NeoGenomics has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.43% of the float of NeoGenomics has been sold short.

Short Interest Ratio / Days to Cover

NeoGenomics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeoGenomics has recently decreased by 21.35%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeoGenomics does not currently pay a dividend.

Dividend Growth

NeoGenomics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.43% of the float of NeoGenomics has been sold short.

Short Interest Ratio / Days to Cover

NeoGenomics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeoGenomics has recently decreased by 21.35%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 7 news articles for NeoGenomics this week, compared to 6 articles on an average week.

Search Interest

Only 9 people have searched for NEO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, NeoGenomics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $550,438.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.40% of the stock of NeoGenomics is held by insiders.

Percentage Held by Institutions

98.50% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NEO Stock Analysis - Frequently Asked Questions

How have NEO shares performed this year?

NeoGenomics' stock was trading at $16.48 at the beginning of 2025. Since then, NEO shares have decreased by 53.8% and is now trading at $7.6150.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) issued its earnings results on Tuesday, April, 29th. The medical research company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by $0.06. NeoGenomics's revenue for the quarter was up 7.6% on a year-over-year basis.
Read the conference call transcript.

Does NeoGenomics have any subsidiaries?

NeoGenomics subsidiaries include Inivata Limited, Trapelo Health, Genesis Acquisition Holding Corp, Genoptix, Clarient Inc, GE Medical Holding AB., Path Labs LLC, and more.

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeoGenomics investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 4/29/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 7/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:NEO
• CIK: 1077183
• Web: www.neogenomics.com
• Phone: (239) 768-0600
• Fax: 239-690-4237
• Employees: 2,200
• Year Founded: 2002

Price Target and Rating

• Average Stock Price Target: $13.83
• High Stock Price Target: $22.00
• Low Stock Price Target: $8.50
• Potential Upside/Downside: +81.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.45
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$78.73 million
• Net Margins: -11.54%
• Pretax Margin: -11.70%
• Return on Equity: -2.21%
• Return on Assets: -1.22%

Debt

• Debt-to-Equity Ratio: 0.38
• Current Ratio: 2.05
• Quick Ratio: 1.95

Sales & Book Value

• Annual Sales: $660.57 million
• Price / Sales: 1.48
• Cash Flow: $0.44 per share
• Price / Cash Flow: 17.21
• Book Value: $7.03 per share
• Price / Book: 1.08

Miscellaneous

• Outstanding Shares: 128,700,000
• Free Float: 125,606,000
• Market Cap: $980.05 million
• Optionable: Optionable
• Beta: 1.63